ASP ISOTOPES INC

ASP Isotopes announces Capital Markets Day in London and an 8‑K filing, spotlighting its Aerodynamic Separation and Quantum Enrichment technologies, and a proposed merger with ENDRA Life Sciences.

ASP Isotopes Inc. announces a capital‑raising exempt offering to boost isotope production for medicine and nuclear power, aiming for global market growth.

ASP Isotopes Inc. shows steady Nasdaq performance, steadily growing trade volume and stable price range as a pre‑commercial isotope producer for medical and nuclear markets.

Explore ASP Isotopes Inc.—a Boca Raton firm pioneering high‑value isotopes for medicine and nuclear power. Learn how its pre‑commercial strategy could shape future profitability.

ASP Isotopes Inc. (ASPI) shows a 32% surge in call options, analyst‑backed $13 target, and high‑potential isotope production—investors eye a near‑term rally.

ASP Isotopes Inc. is a Nasdaq‑listed advanced‑materials company specializing in low‑volume isotopes for medical and nuclear applications. The firm recently filed a Form 8‑K, confirming regulatory compliance, and secured class certification in a laws…

ASP Isotopes expands in advanced materials and photonics, endowing a University of the Witwatersrand chair while filing SEC updates and exploring energy and cross‑border deals—boosting research and investor visibility.

ASP Isotopes Inc. has made significant strides in isotope production, operationalizing new facilities, forming partnerships, and planning expansions, positioning the company as a key player in the global industry.

ASP Isotopes Inc. is a pre-commercial stage company making waves in the advanced materials sector with its high-value, low-volume isotopes, but faces financial challenges as it navigates the path to commercialization.